Key Takeaways
1. Bone Biologics is seeking patent protection for its rhNELL-1 polypeptide, aimed at improving targeted bone growth.
2. Spinal fusion surgeries often face high failure rates and complications from current treatments, such as uncontrolled bone growth.
3. NELL-1 protein has shown promise in stimulating precise bone growth and preventing fat cell development, enhancing fusion reliability.
4. The company is conducting a pilot clinical trial in Australia for a NELL-1-based bone graft device for degenerative disc disease.
5. The patent application has positively impacted the company’s stock price, reflecting investor optimism about its potential in the spinal implant industry.
Bone Biologics has declared its intention to pursue patent protection for its rhNELL-1 polypeptide, a distinct protein aimed at enhancing targeted bone growth. Although this filing is just the beginning, it demonstrates the company’s strong belief in a technology that could provide a safer and more effective option for the countless patients who undergo spinal fusion surgeries every year.
Spinal Fusion and Its Challenges
Spinal fusion is a routine procedure used to alleviate severe back pain by fusing two or more vertebrae together, but it often comes with a high rate of failure. The existing treatments frequently depend on bone grafts or powerful growth factors that sometimes result in issues, like uncontrolled bone growth outside the intended area.
The Role of NELL-1
Bone Biologics focuses on the NELL-1 protein, a growth factor that naturally plays a role in bone formation. Research prior to clinical trials has indicated that NELL-1 can effectively stimulate significant bone growth exactly where it is required, while also preventing the development of fat cells, a common side effect seen with other biologics. This specific targeting could enhance the reliability of fusions and reduce the risk of complications.
“This patent application is a significant milestone in our quest to provide effective treatments for patients undergoing spine fusion,” said Jeffrey Frelick, CEO of Bone Biologics.
Clinical Trials and Future Steps
The company is presently running a pilot clinical trial of its NELL-1-based bone graft device in Australia aimed at patients suffering from degenerative disc disease. Obtaining patent protection in the U.S. is a vital component of its strategy as it seeks to further its clinical program and ultimately pursue FDA approval. The announcement of the patent filing led to a notable increase in the company’s stock price, indicating investor enthusiasm regarding the potential of this technology to shake up the spinal implant industry.
Source:
Link
Leave a Reply